As a feature of this year�s 84th annual meeting of the Japanese Pharmacological Society (JPS) taking place March 22nd to 24th in Yokohama Japan, the first ever formal Japanese Caucasian bridging TQT analysis is due to  be presented by Professor Sugiyama of Taiho University and Dr Jorg Taubel of Richmond Pharmacology Ltd.  The analysis was carried out jointly between the Department of Pharmacology of Toho University, the Cardiovascular Sciences Research Centre at St Georges University of London and Richmond Pharmacology Ltd.Japan and BeyondIn 2010, Japan adopted the ICH E14 guideline requiring the submission of TQT studies for new product license applications which may need to be done partly or fully in Japanese subjects.In 1998, the International Conference on Harmonisation (ICH)  Guideline on Ethnic Factors in the Acceptability of Foreign Clinical Data  (E5) was adopted.  This, coupled with the acceptance of the PDMA in 2007 of clinical data from non-Japanese patients, has helped to bring NCE s to the Japanese pharmaceutical market in both a cost and time efficient manner.Trust Well Invested (E5) was adopted.  This, coupled with the acceptance of the PDMA in 2007 of clinical data from non-Japanese patients, has helped to bring NCE

  • TQT Studies in Japanese and other ethnicities
  • First-in-Japanese
  • Ascending Single and Multiple  (SAD and MAD Studies)
  • Combined protocols such as bridging, SAD and MAD and food effect

Partnering with JapanIn order to facilitate the collaboration with Japanese sponsors, RICHMOND PHARMACOLOGY is also partnered with AcroNet, a Japan based full service clinical CRO.  Acronet provide a high quality, expert service and like Richmond Pharmacology, are dedicated to the development of the pharmaceutical and medical field and most importantly people's health.

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event